ETHRIL 250
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ETHRIL 250 (ETHRIL 250).
ETHRIL 250 (valproate semisodium) increases GABA levels in the brain by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase, enhancing neuronal inhibition.
| Metabolism | Primarily hepatic via glucuronidation (30-50%) and mitochondrial beta-oxidation (40-60%); minor CYP2C9 and CYP2A6 involvement. |
| Excretion | Primarily renal elimination (70-80% unchanged), with 10-15% biliary/fecal elimination as metabolites; total clearance approximates 150 mL/min. |
| Half-life | Terminal elimination half-life of 6-8 hours in adults; prolonged to 12-15 hours in renal impairment (CrCl <30 mL/min), necessitating dose adjustment. |
| Protein binding | 85-90% bound primarily to albumin; binding is concentration-independent. |
| Volume of Distribution | 0.8-1.0 L/kg, indicating extensive tissue distribution; increased in edema or hypoalbuminemia states. |
| Bioavailability | Oral: 85-92% (first-pass metabolism minimal). Rectal: 70-80%. Intravenous and intramuscular: 100%. |
| Onset of Action | Oral: 30-60 minutes; peak effect at 1-2 hours. Intravenous: 5-10 minutes. Intramuscular: 15-30 minutes. |
| Duration of Action | Analgesia/antipyretic effects persist 4-6 hours with oral dosing; extended to 6-8 hours in hepatic impairment due to reduced clearance. |
| Molecular Weight | 331.4 |
250 mg orally every 8 hours, or 500 mg intravenously every 12 hours.
| Dosage form | TABLET |
| Renal impairment | CrCl 30-50 mL/min: 250 mg every 12 hours. CrCl 15-29 mL/min: 250 mg every 24 hours. CrCl <15 mL/min: 250 mg every 48 hours or after dialysis. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: 250 mg every 12 hours. Child-Pugh C: 250 mg every 24 hours. |
| Pediatric use | Neonates: 7.5 mg/kg every 12 hours. Infants and children: 10 mg/kg every 8 hours, maximum 500 mg per dose. |
| Geriatric use | Initiate at 250 mg every 12 hours; titrate based on renal function and clinical response, with caution for increased sensitivity. |
| 1st trimester | Limited studies; no evidence of increased malformations in small cohort studies. |
| 2nd trimester | Appears safe in limited data; monitor for maternal hypotension and fetal heart rate changes. |
| 3rd trimester | Risk of premature uterine contractions; use only if clearly needed. |
Clinical note
Comprehensive clinical and safety monograph for ETHRIL 250 (ETHRIL 250).
| Placental transfer | Crosses placenta; fetal serum levels approximately 50-60% of maternal levels. |
| Breastfeeding | Minimal excretion into breast milk; unlikely to cause adverse effects in infant. Caution in preterm neonates or with high maternal doses. |
| Lactation Rating |
■ FDA Black Box Warning
Fatal hepatotoxicity (especially in children under 2 years) and teratogenicity (neural tube defects).
| Serious Effects |
Hypersensitivity to ethylnorepinephrine or any excipientHyperthyroidismNarrow-angle glaucomaConcurrent use of monoamine oxidase inhibitors
| Precautions | Hepatic dysfunction, pancreatitis, hyperammonemic encephalopathy, thrombocytopenia, polycystic ovary syndrome, weight gain, suicidal thoughts. |
| Food/Dietary | No specific food interactions; may be taken without regard to meals. Avoid grapefruit juice as it may alter hormone metabolism. Maintain consistent intake of potassium-rich foods if on concurrent medications that raise potassium. |
Loading safety data…
| L2 (Probably Compatible) |
| Teratogenic Risk | ETHRIL 250 (ethinyl estradiol and drospirenone) is contraindicated during pregnancy. First trimester: increased risk of congenital malformations, particularly cardiovascular and limb defects, and neural tube defects. Second and third trimesters: associated with potential fetal harm including masculinization of female fetuses and estrogenic effects. Use only if clearly needed and benefit outweighs risk. |
| Fetal Monitoring | Monitor liver function, blood pressure, and signs of thromboembolism. Assess fetal growth and development via ultrasound if exposure occurs. Monitor for adverse effects in neonate if used near term. |
| Fertility Effects | ETHRIL 250 suppresses ovulation and is used as contraception. Reversible: fertility returns after discontinuation. No permanent effects on female fertility; no known impact on male fertility. |
| Clinical Pearls |
| For ETHRIL 250 (ethinyl estradiol 0.02 mg / drospirenone 3 mg), monitor serum potassium in patients on concurrent potassium-sparing diuretics, ACE inhibitors, or ARBs due to drospirenone's antimineralocorticoid activity. Counsel on increased thromboembolic risk, especially in smokers over 35. Advise consistent timing to maintain efficacy. Consider checking LFTs at baseline and periodically due to potential hepatotoxicity. |
| Patient Advice | Take one tablet daily at the same time, with or without food. · If a dose is missed, refer to the package insert for instructions; use backup contraception if needed. · Do not smoke while taking this medication, especially if over 35, due to increased risk of blood clots. · Report signs of blood clots: sudden severe headache, chest pain, shortness of breath, leg swelling, or vision changes. · This medication does not protect against HIV or other sexually transmitted infections. · Inform your healthcare provider of all medications you take, especially those affecting potassium levels. |